The FDA expanded the indication for nilotinib for the treatment of children with newly diagnosed Philadelphia chromosome–positive chronic myeloid leukemia in the chronic phase who are at least a year old, as well as those who are resistant to or cannot tolerate imatinib. The drug is the third tyrosine kinase inhibitor approved for children with this rare cancer.
https://ift.tt/2JkBTL1
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου